<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Social anxiety disorder in adults: Treatment overview</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Social anxiety disorder in adults: Treatment overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Social anxiety disorder in adults: Treatment overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Murray B Stein, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles T Taylor, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter P Roy-Byrne, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 29, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1566219676"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Social anxiety disorder (SAD), also known as social phobia, is a condition marked by extreme fear of situations that involve possible scrutiny by others. The individual avoids these situations due to fear of humiliation or embarrassment or endures them with intense anxiety.</p><p>SAD is a prevalent condition, estimated to affect between 4 and 10 percent of the adult United States population over a 12-month period. SAD typically begins in childhood or adolescence and, untreated, can be associated with the subsequent development of major depression, substance use disorder, and other mental health problems. The disorder can be associated with extensive functional impairment and reduced quality of life [<a href="#rid1">1</a>].</p><p>This topic presents our treatment overview for SAD and SAD, performance only. The epidemiology, pathogenesis, clinical manifestations, assessment, and diagnosis of SAD are discussed separately, as is discussion of treatment with psychotherapy. (See  <a class="medical medical_review" href="/z/d/html/15537.html" rel="external">"Social anxiety disorder in adults: Epidemiology, clinical features, assessment, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/14635.html" rel="external">"Social anxiety disorder in adults: Psychotherapy"</a>.)</p><p class="headingAnchor" id="H3773408540"><span class="h1">PRIOR TO TREATMENT</span></p><p class="headingAnchor" id="H3021420628"><span class="h2">Decision to treat</span><span class="headingEndMark"> — </span>Patient preference is the primary factor in the determining the need for treatment. After the diagnosis of social anxiety disorder (SAD) is established, we review the impact that the disorder has had on the individual’s quality of life. We review the individual’s future goals and how these may be affected by the disorder. We use these discussions to help the patient decide on whether to pursue treatment.</p><p>Not all patients with SAD require immediate treatment. In particular, young adults may benefit from education about their disorder and may need time to reflect on the extent to which social anxiety and avoidance have negatively impacted their lives. It is not unusual for a newly diagnosed patient with SAD to be surprised that these symptoms can diminish or resolve with treatment as opposed to being an inalterable aspect of their self. The need for treatment of SAD is rarely an emergency. Most patients have had SAD for many years, and the decision to seek a diagnosis may have taken a long time.</p><p class="headingAnchor" id="H836496998"><span class="h2">Selection of treatment modality</span></p><p class="headingAnchor" id="H2813598167"><span class="h3">Social anxiety disorder, generalized</span><span class="headingEndMark"> — </span>Our choice of treatment for SAD, generalized, is based on informed patient preference.</p><p>Treatment of SAD with either cognitive-behavioral therapy (CBT) or pharmacotherapy has been found to reduce symptoms of social anxiety, as compared with placebo [<a href="#rid2">2-5</a>]. While some studies suggest improved response when using a combination of medication and psychotherapy (ie, CBT), other studies have not shown substantive differences compared with either modality alone. Given the uncertainties, we favor initiating therapy with either psychotherapy or medication while reserving combination therapy for those that prefer combination treatment and for selected individuals with a suboptimal response.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comparing CBT and pharmacotherapy </strong>– Evidence from randomized trials comparing CBT with pharmacotherapy for SAD has not demonstrated clear superiority of one treatment modality over the other [<a href="#rid2">2-5</a>].</p><p></p><p class="bulletIndent1">As an example, in a randomized trial, 128 patients with SAD were assigned to treatment in one of the following: the monoamine oxidase inhibitor (MAOI) <a class="drug drug_general" data-topicid="9762" href="/z/d/drug information/9762.html" rel="external">phenelzine</a>, group CBT tailored for SAD, the combination of phenelzine and group CBT, or placebo pill [<a href="#rid2">2</a>]. After 12 weeks, response rates (as measured by the Clinical Global Improvement scale) between the CBT group and the phenelzine group were similar and greater than response rates compared with the placebo group (47 versus 54 versus 33 percent, respectively).</p><p></p><p class="bulletIndent1">While the onset of symptom response may be faster with pharmacotherapy, speed of onset is rarely an important attribute in the treatment of SAD, as most patients have had the disorder for many years and a difference of a few weeks in response time is largely irrelevant. CBT appears to result in a more durable response [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combining CBT and pharmacotherapy</strong> – Clinical trials have yielded mixed results comparing the combination of CBT and medication to either modality individually [<a href="#rid2">2-4</a>]. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a randomized trial, 295 subjects with SAD were assigned to one of five treatment groups: <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>, group CBT, combined group CBT and placebo, combined group CBT and fluoxetine, or placebo [<a href="#rid3">3</a>]. A higher proportion of patients responded to fluoxetine (51 percent), group CBT (52 percent), combined group CBT and placebo (51 percent) and combined group CBT and fluoxetine (54 percent) than to placebo (32 percent). However, the group receiving combined medication and CBT did not differ significantly in response compared with groups receiving either monotherapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a randomized trial of 128 patients with SAD (described above), combined group CBT-phenelzine resulted in higher response rates compared with either CBT or <a class="drug drug_general" data-topicid="9762" href="/z/d/drug information/9762.html" rel="external">phenelzine</a> as monotherapy (72 versus 47 versus 54 percent, respectively) [<a href="#rid2">2</a>].</p><p></p><p class="headingAnchor" id="H3065435645"><span class="h3">Social anxiety disorder, performance only</span><span class="headingEndMark"> — </span>For SAD, performance only, our preference is treatment with CBT, particularly if the individual will encounter performance situations on a recurring basis (see <a class="local">'Patients who prefer psychotherapy'</a> below). However, for a patient requesting help with a single or rarely recurring performance (ie, giving a toast at a friend’s wedding) pharmacotherapy is a suitable alternative. Further discussion of the treatment of SAD, performance only, is found below. (See <a class="local">'Social anxiety disorder, performance only'</a> below and  <a class="medical medical_review" href="/z/d/html/15537.html" rel="external">"Social anxiety disorder in adults: Epidemiology, clinical features, assessment, and diagnosis", section on 'Performance anxiety'</a>.)</p><p class="headingAnchor" id="H3661564324"><span class="h1">PATIENTS WHO PREFER PSYCHOTHERAPY</span><span class="headingEndMark"> — </span>For patients with either social anxiety disorder (SAD), generalized or SAD, performance only, who have chosen treatment with psychotherapy, we suggest first-line treatment with either individual or group cognitive-behavioral therapy (CBT) customized for SAD.</p><p class="headingAnchor" id="H4252063353"><span class="h2">CBT as preferred initial modality</span><span class="headingEndMark"> — </span>In CBT tailored for SAD, the therapist works with the patient to identify and challenge maladaptive cognitions associated with social situations and to reduce avoidance or safety behaviors when confronting feared situations [<a href="#rid7">7,8</a>]. (See  <a class="medical medical_review" href="/z/d/html/14635.html" rel="external">"Social anxiety disorder in adults: Psychotherapy"</a>.)</p><p>Administration, components and comparative efficacy of various forms of psychotherapy including CBT, CBT tailored for SAD, attention retraining [<a href="#rid9">9-11</a>], interpersonal psychotherapy [<a href="#rid12">12</a>], and psychodynamic therapy in the treatment of SAD are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/14635.html" rel="external">"Social anxiety disorder in adults: Psychotherapy"</a>.)</p><p>Placebo-controlled studies suggest that CBT may be the most efficacious form of psychotherapy for SAD [<a href="#rid8">8,13-16</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of five randomized trials totaling 318 patients found traditional CBT to be efficacious for SAD compared with placebo control (odds ratio 4.21, 95% CI 2.07-8.98) [<a href="#rid13">13</a>]. Medium to large positive effects (Hedges g 0.84, 95% CI 0.72; 0.97) on social anxiety symptoms have also been seen for group CBT tailored for SAD compared with waitlist [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A network meta-analysis including 101 clinical trials suggested that CBT was superior to no treatment, pill placebo, psychological control conditions, and psychotherapies including psychodynamic psychotherapy, interpersonal psychotherapy, mindfulness, and supportive psychotherapy [<a href="#rid15">15</a>].</p><p></p><p>However, those clinical trials directly comparing CBT with other forms of psychotherapy did not consistently favor either treatment [<a href="#rid17">17-19</a>]. As an example, in a trial 495 subjects with SAD were randomly assigned to treatment with manual-guided CBT, manual-guided psychodynamic psychotherapy or waitlist condition [<a href="#rid18">18</a>]. Both CBT and psychodynamic therapy were superior to wait list on measures of response rate and remission rate. While individuals receiving CBT demonstrated superior response compared with psychodynamic therapy on some measures of social anxiety at postassessment, differences were small in magnitude and not found during follow-up at 24 months [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H567623267"><span class="h2">For good response to CBT</span><span class="headingEndMark"> — </span>We consider a response to treatment to entail substantial reduction in anticipatory fear and phobic avoidance, along with reduced anxiety when in social situations.</p><p>We encourage patients with a response to CBT to continue practicing the cognitive and behavioral skills learned in session on a maintenance basis. We recommend the inclusion of maintenance sessions (eg, two to four visits per year) as part of a relapse-prevention plan.</p><p class="headingAnchor" id="H2377031254"><span class="h2">For partial or no response to CBT</span></p><p class="headingAnchor" id="H48422876"><span class="h3">Initial adjustments</span><span class="headingEndMark"> — </span>We reassess patients with partial or no response to a full trial of CBT for remaining cognitive errors or avoidance strategies contributing to maintenance of social anxiety; we address these in additional weekly CBT sessions over 8 to 12 weeks. Additionally, we reassess the patient for comorbid disorders such as major depression, complicated grief, interpersonal trauma, or substance use disorder. We address these as needed. (See  <a class="medical medical_review" href="/z/d/html/14635.html" rel="external">"Social anxiety disorder in adults: Psychotherapy", section on 'Strategies for nonresponse'</a>.)</p><p>If initial adjustments do not lead to desired response to treatment, we typically augment the psychotherapy with a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI). However, we prioritize patient preference. For example, if an individual wishes to continue treatment with psychotherapy only, we follow their preference. Choice of medication and subsequent pharmacologic management of individuals with SAD is discussed below. (See <a class="local">'Patients who prefer psychotherapy'</a> above and <a class="local">'Selecting a medication'</a> below and <a class="local">'Subsequent pharmacologic management'</a> below.)</p><p class="headingAnchor" id="H3467609088"><span class="h1">MEDICATION MANAGEMENT</span><span class="headingEndMark"> — </span>For patients with social anxiety disorder (SAD), generalized type, who prefer medication management (with or without psychotherapy) or in those who have had a partial or no response to psychotherapy, our pharmacologic management is discussed below.</p><p class="headingAnchor" id="H1760562087"><span class="h2">Selecting a medication</span><span class="headingEndMark"> — </span>Our preference for pharmacologic management of SAD is first-line treatment with a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI). As there is no evidence supporting the superiority of one SSRI or SNRI over another, our choice is based on patient preference, clinician familiarity with medications, past history, side effects, and family history  (<a class="graphic graphic_table graphicRef81315" href="/z/d/graphic/81315.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">table 2</a>). (See <a class="local">'Efficacy of SSRIs and SNRIs'</a> below.)</p><p>Other medications with efficacy in SAD are supported by fewer trials, have more problematic side effect profiles (monoamine oxidase inhibitors [MAOIs] [<a href="#rid2">2,20</a>] and benzodiazepines [<a href="#rid21">21,22</a>]), or show less robust treatment effects (<a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> [<a href="#rid23">23</a>] and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> [<a href="#rid24">24-26</a>]) when compared with placebo [<a href="#rid15">15,20,27-30</a>]. These agents are generally reserved for treatment of those with suboptimal response to SSRIs or SNRIs. (See <a class="local">'Other agents with limited support'</a> below.)</p><p>Our preference for pharmacologic management of SAD, performance only, is described below. (See <a class="local">'Social anxiety disorder, performance only'</a> below.)</p><p class="headingAnchor" id="H314312472"><span class="h2">Initiating treatment</span><span class="headingEndMark"> — </span>To avoid side effects, when starting treatment with an antidepressant (eg, SSRI, SNRI), we are vigilant to begin at the lower end of the starting dose range and titrate gradually.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>SSRIs </strong>–<strong> </strong>SSRIs are the best studied and the most commonly prescribed of the medication treatments for SAD [<a href="#rid31">31</a>]. Higher doses of SSRIs typically result in better outcomes, so the dose is usually pushed to the maximum tolerated by the individual (unless an excellent response is attained at a lower dose, at which point the dose would be held there to ascertain stability of the response).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We typically start <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a> at 10 mg/day orally and increase to a therapeutic dose of 20 mg/day after a few days. We maintain at this dose for six weeks while monitoring symptomatically. If the patient does not have an adequate response, we increase by 10 mg every two to three weeks, as tolerated, until desired effect is seen or maximum dose of 60 mg per day is reached.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We typically start <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> at 25 mg/day orally and after one week increase to 50 mg per day. We maintain at this dose for four to six weeks. If the patient does not have an adequate response, we increase by 50 mg increments every two to three weeks, as tolerated, until desired effect is seen or a maximum of 250 mg/day is reached.</p><p></p><p class="bulletIndent1">Common side effects of SSRIs include restlessness, agitation, headache, diarrhea, nausea, and insomnia. SSRIs also cause sexual dysfunction in as many as 50 percent of patients. Starting and maintenance doses of SSRIs and their side effects are presented on the tables  (<a class="graphic graphic_table graphicRef81315" href="/z/d/graphic/81315.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SNRIs </strong>– When prescribing extended-release <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a>, we begin at 37.5 mg/day taken orally. We continue for three to seven days then increase to 75 mg (low end of the therapeutic range) and monitor for four to six weeks. If further increases are needed, we increase by 37.5 mg on a weekly basis, as tolerated, until response is seen or a maximum dose of 225 mg daily is reached.</p><p></p><p class="bulletIndent1">As <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a> can increase blood pressure, particularly in higher doses, we routinely check blood pressure at each visit in individuals with a history of hypertension [<a href="#rid32">32</a>]. Although usually small, the increases can be significant in some patients.</p><p></p><p class="bulletIndent1">Other common side effects of <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a> are nausea, dizziness, insomnia, sedation, and constipation. Starting and usual maintenance doses of SNRIs and their side effects are found on the tables  (<a class="graphic graphic_table graphicRef81315" href="/z/d/graphic/81315.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/1713.html" rel="external">"Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects"</a>.)</p><p></p><p class="headingAnchor" id="H3769794228"><span class="h2">Length of trial, monitoring, homework</span><span class="headingEndMark"> — </span>We consider 10 to 12 weeks of treatment including six weeks at the highest tolerated dose within the therapeutic range to be a full therapeutic trial. The clinical effects of SSRI and SNRI treatment for SAD typically require four to six weeks to have a significant impact; maximal benefit can require as long as 16 weeks [<a href="#rid6">6</a>].</p><p>We use the Liebowitz Social Anxiety Scale (LSAS) to monitor treatment response at each visit. The scale has good psychometric properties and can be used for clinician assessment or patient self-report [<a href="#rid33">33,34</a>]. (See  <a class="medical medical_review" href="/z/d/html/15537.html" rel="external">"Social anxiety disorder in adults: Epidemiology, clinical features, assessment, and diagnosis", section on 'Monitoring'</a>.)</p><p>Whenever pharmacotherapy is prescribed for SAD, we recommend that the patient enter the previously feared social situations to “test out” the effects of the medication and to learn that these situations are safe and can be tolerated. Although there are no research data to support this claim, there is some reason to believe that those patients who do the most “practicing” and “expanding of their social horizons” while on medication are the ones who have the best longer-term outcomes. One of the first indications of response is the patient’s report of feeling less “self-conscious” in typical social situations.</p><p class="headingAnchor" id="H3720154828"><span class="h2">Good response to treatment</span><span class="headingEndMark"> — </span>For patients who have an adequate response to initial trial of SSRI or SNRI, we continue treatment for at least one year. In individuals who have maintained improvements over that period of time we gradually (over two to three months) taper off of medications. However, our treatment plan is individualized to address other factors such as difficulty reaching stabilization, level of psychosocial impairment, history of prior exacerbations after medication discontinuation, or the presence of active comorbid disorders. For example, in an individual whose symptoms caused significant psychosocial disruption and in whom stabilization may have been difficult, we would likely continue medication for greater than one year.</p><p class="headingAnchor" id="H2683703491"><span class="h2">Partial or no response to treatment</span></p><p class="headingAnchor" id="H2322839181"><span class="h3">Initial adjustments</span><span class="headingEndMark"> — </span>We reassess patients who do not respond to a full trial of SSRI or SNRI medication for adherence to treatment including reviewing side effects that may be limiting adherence. Additionally, we reassess for the presence of comorbid disorders such as major depression, complicated grief, substance use, or interpersonal trauma. We address these as needed.</p><p class="headingAnchor" id="H58522291"><span class="h3">Augmentation versus changing medication</span><span class="headingEndMark"> — </span>Our preference is augmentation of a partial response to a medication and change in agent for nonresponse to a medication.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Partial response</strong> – For a partial response to the first or second SSRI/SNRI, our next step is augmentation of the SSRI. Our choice of augmenting agent is based on whether there is a history of a substance use disorder. (See <a class="local">'No substance use disorder'</a> below and <a class="local">'Substance use disorder'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No response </strong>–<strong> </strong>For all individuals with no response to initial SSRI or SNRI, we try a full trial of a second SSRI or SNRI (see <a class="local">'Length of trial, monitoring, homework'</a> above). We use the same factors in choosing the second antidepressant as we do for the first. (See <a class="local">'Selecting a medication'</a> above.)</p><p></p><p class="bulletIndent1">For no response to two SSRIs/SNRIs, we change to another agent. Our preference for the next agent depends on whether there is a history of a substance use disorder. (See <a class="local">'No substance use disorder'</a> below and <a class="local">'Substance use disorder'</a> below.)</p><p></p><p class="bulletIndent1">A randomized clinical trial of patients with no or partial response after 10 weeks of <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> treatment compared continued use of sertraline at the same dose with switching to <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a> [<a href="#rid35">35</a>]. Both groups improved somewhat over time, but no difference in response was seen between the two groups. While some patients may accrue additional benefit by remaining on their initial SSRI or SNRI beyond 10 weeks of treatment, it is difficult to justify leaving a patient with minimal or no response on the same medication for an extended duration.</p><p></p><p class="headingAnchor" id="H1179397338"><span class="h2">Efficacy of SSRIs and SNRIs</span><span class="headingEndMark"> — </span>Evidence supporting the use of SSRIs or the SNRI, <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a>, for the treatment of SAD in adults includes:</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of trials comparing SSRIs with placebo (seven trials, n = 896), treatment with SSRIs resulted in greater symptom reduction than placebo on the LSAS. The effect size was moderate [<a href="#rid20">20</a>]. Additionally, treatment with SSRIs led to greater reduction in symptoms such as depression, or associated disability than placebo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a trial investigating the efficacy of treatment of SAD with <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a>, 183 patients with SAD were randomly assigned to receive 11 weeks of paroxetine (20 to 50 mg) versus placebo [<a href="#rid36">36</a>]. At treatment end, subjects in the paroxetine group were more likely to be “much improved” or “very much improved” as compared with patients treated with placebo (55 versus 24 percent). Additionally, the percent improvement on the LSAS was greater in the paroxetine group as compared with placebo group (39 versus 17 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial, 440 patients with SAD were assigned to treatment with <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a> (75 to 225 mg daily extended release), <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a> (20 to 50 mg daily), or placebo [<a href="#rid27">27</a>]. After 12 weeks, response rates were similar in the venlafaxine and paroxetine groups, both of which were superior to placebo (59 and 63 versus 36 percent response, respectively). Medication discontinuation rates were similar with venlafaxine and paroxetine, but adverse events leading to a reduction in dosage were more common with venlafaxine (16 versus 8 percent).</p><p></p><p class="headingAnchor" id="H378060446"><span class="h1">SUBSEQUENT PHARMACOLOGIC MANAGEMENT</span><span class="headingEndMark"> — </span>For individuals who have had a poor or partial response to the above measures (ie, poor response to two selective trials of serotonin reuptake inhibitor [SSRI] and serotonin-norepinephrine reuptake inhibitor [SNRI], or partial response to either trial), our preference for subsequent treatment is based on whether there is a history of a substance use disorder. We typically avoid benzodiazepines in individuals with substance use disorders.</p><p class="headingAnchor" id="H4002054983"><span class="h2">No substance use disorder</span><span class="headingEndMark"> — </span>We prefer to use benzodiazepines as the next agent in those without an active or history of a substance use disorder. As above, we augment the SSRI/SNRI with a benzodiazepine for partial response, we discontinue the SSRI/SNRI and switch to a benzodiazepine for those with no response to SSRI/SNRI treatment. Choice, administration, and titration of benzodiazepines are discussed below. (See <a class="local">'Benzodiazepine treatment'</a> below.)</p><p>If symptoms persist, our next choice of agent depends on the level of response to the benzodiazepine.</p><p class="bulletIndent1"><span class="glyph">●</span>For no response to treatment with the benzodiazepine our preference is discontinuation of the benzodiazepine and treatment with a monoamine oxidase inhibitor (MAOI) as monotherapy. If MAOI is ineffective, unable to be taken (eg, due to inability to follow dietary restrictions), or if side effects limit treatment, our next steps are sequential trials of <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">buspirone</a>, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>. (See <a class="local">'Monoamine oxidase inhibitors'</a> below and <a class="local">'Other agents with limited support'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For partial response to the benzodiazepine, our preference is augmentation. We do not use MAOI as augmentation in individuals on SSRI/SNRI due to potential for serotonin syndrome. In these cases, our preference is sequential augmentation trials of <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">buspirone</a>, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>. (See <a class="local">'Monoamine oxidase inhibitors'</a> below and <a class="local">'Other agents with limited support'</a> below.)</p><p></p><p>As minimal evidence supports the use of <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">buspirone</a>, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> as agents for monotherapy or augmentation treatment of social anxiety disorder (SAD), our choice is made based on patient preference and physician level of comfort and familiarity with the various agents.</p><p>Some individuals may wish to discontinue medication and switch to cognitive-behavioral therapy (CBT) treatment only. Additionally, CBT can be added to any pharmacologic regimen at any time. The choice of treatment is typically made based on patient preference [<a href="#rid31">31</a>]. (See <a class="local">'Patients who prefer psychotherapy'</a> above.)</p><p class="headingAnchor" id="H3338412953"><span class="h2">Substance use disorder</span><span class="headingEndMark"> — </span>We typically avoid the use of benzodiazepines in individuals with a history of a substance use disorder. If no response to SSRI treatment is seen, we prefer changing from the SSRI to an MAOI as monotherapy. In this case, a washout period is needed prior to starting the MAOI. We do not add the MAOI to the SSRI due to the potential for serotonin syndrome. Choice of agent, initial dose, titration, and dietary and pharmacologic precautions necessary when using MAOI are discussed below.(See <a class="local">'Monoamine oxidase inhibitors'</a> below.)</p><p>If treatment with an MAOI leads to no response, we try sequential trials of <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">buspirone</a>, <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>, or <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>. Our choice is made based on patient preference, physician level of comfort and familiarity with the various agents.</p><p>There is little evidence available to guide augmentation of an SSRI/SNRI for patients with a history of a substance use disorder and a <strong>partial response</strong> to the serotonergic drug [<a href="#rid37">37</a>]. The MAOI <a class="drug drug_general" data-topicid="9762" href="/z/d/drug information/9762.html" rel="external">phenelzine</a> cannot<strong> </strong>be used, because of the risk of serotonin syndrome with concurrent use of phenelzine and an SSRI/SNRI. For individuals with a partial response to SSRI/SNRI treatment, our choice is subsequent augmentation trials of <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">buspirone</a>, <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>, or <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>. As minimal evidence supports that choice of these agents in the treatment of SAD, our choice is made based on patient preference and physician level of comfort and familiarity with the various agents.</p><p>If these strategies are not effective, patients with a history of substance use disorder could be judiciously prescribed an adjunctive benzodiazepine provided that the substance use disorder was not active or recent (eg, in the past 12 months) and the patient’s use of the medication was carefully monitored. (See <a class="local">'No substance use disorder'</a> above.)</p><p>Some individuals may wish to discontinue medication and switch to CBT treatment only. Additionally, CBT can be added to any pharmacologic regimen at any time. The choice of treatment is typically made based on patient preference [<a href="#rid31">31</a>]. (See <a class="local">'Patients who prefer psychotherapy'</a> above.)</p><p class="headingAnchor" id="H3720840210"><span class="h2">Benzodiazepine treatment</span><span class="headingEndMark"> — </span>To minimize side effects such as sedation, we begin treatment with the benzodiazepine at a low dose and titrate slowly until satisfactory response is seen. Our preference is to a use an agent with slower onset and longer-half life, such as <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a>. When using clonazepam, as either monotherapy or as an augmenting agent, we begin at 0.25 to 0.50 mg twice daily and we increase by 0.5 mg weekly to the maximum tolerated dose within the therapeutic range up to a maximum dose of 2 mg twice daily.</p><p>The potential for misuse and physiologic dependence limit the use of these agents. We are vigilant to discuss these issues with the patient and their family prior to beginning a benzodiazepine.</p><p class="headingAnchor" id="H3536680232"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Small randomized trials have found the high-potency benzodiazepines <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">alprazolam</a> [<a href="#rid21">21</a>] and <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a> [<a href="#rid22">22</a>], to be efficacious as monotherapy in the reduction of SAD symptoms.</p><p>Randomized trials have found evidence in support of augmentation of an SSRI with <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a> [<a href="#rid35">35,38</a>]. For example, in a trial, 181 patients with SAD who had no more than a partial response to 10 weeks of <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> were randomly assigned to 12 weeks of continuation on sertraline augmented by either clonazepam or placebo [<a href="#rid35">35</a>]. Treatment with sertraline plus placebo was associated with a greater drop in symptom severity and disability as measured by the Liebowitz Social Anxiety Scale (LSAS). Supplemental analysis showed that the overall response rate (as defined by LSAS score ≤50) was greater for those treated with sertraline plus clonazepam as compared with sertraline plus placebo (56 versus 36 percent).</p><p class="headingAnchor" id="H2969774822"><span class="h2">Monoamine oxidase inhibitors</span><span class="headingEndMark"> — </span>The MAOIs have the longest track record of use for SAD, having been essentially the only pharmacotherapy available (though never approved by the US Food and Drug Administration [FDA]) for SAD prior to the advent of the SSRIs. However, MAOI-related side effects, and dietary restrictions limit their use.</p><p>MAOIs cause inhibition of the MAO enzyme. Irreversible MAOIs, such as <a class="drug drug_general" data-topicid="9762" href="/z/d/drug information/9762.html" rel="external">phenelzine</a>, are incompatible with certain foods and medications (eg, cheese, aged meats, alcohol, over-the-counter cold preparations). A potentially fatal hypertensive reaction can occur if users of MAOIs consume food containing tyramine; thus, use of irreversible MAOIs must be accompanied by a low tyramine diet. Their use is also contraindicated with other antidepressants, and over the counter or prescribed medications containing sympathomimetic stimulants or <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">dextromethorphan</a>. </p><p>A washout period is needed after stopping the SSRI/SNRI and before starting the MAOI to avoid precipitation of a hypertensive reaction. We typically wait one to two weeks for most SSRIs/SNRIs and five to six weeks following cessation of <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>. (See  <a class="medical medical_review" href="/z/d/html/1715.html" rel="external">"Monoamine oxidase inhibitors (MAOIs): Pharmacology, administration, safety, and side effects"</a>.)</p><p>We begin <a class="drug drug_general" data-topicid="9762" href="/z/d/drug information/9762.html" rel="external">phenelzine</a> at 15 mg once or twice daily for two weeks then increase by 15 mg weekly as tolerated until desired effect is seen or a total daily dose of 60 to 90 mg/day is reached. It can take four to six weeks for a response to occur, and longer for maximal response to be attained.</p><p>Several randomized trials have found that <a class="drug drug_general" data-topicid="9762" href="/z/d/drug information/9762.html" rel="external">phenelzine</a> is an efficacious treatment for SAD, with approximately one-half of patients responding with a clinically significant reduction in symptoms [<a href="#rid20">20</a>]. A randomized trial that included a phenelzine arm found a response rate of 54 percent for phenelzine compared with 33 percent for placebo [<a href="#rid2">2</a>]. </p><p>MAOIs are generally reserved for SAD refractory to other treatments. Some practitioners feel that MAOIs are more effective than SSRIs or SNRIs, though no comparative efficacy trials have been conducted to substantiate this belief. (See  <a class="medical medical_review" href="/z/d/html/1715.html" rel="external">"Monoamine oxidase inhibitors (MAOIs): Pharmacology, administration, safety, and side effects"</a>.)</p><p class="bulletIndent1">Other adverse effects common at therapeutic doses include postural hypotension, insomnia, paradoxical daytime sedation, sexual dysfunction, and weight gain. In many instances, these side effects can be dose limiting.</p><p></p><p class="headingAnchor" id="H1247697367"><span class="h1">OTHER AGENTS WITH LIMITED SUPPORT</span><span class="headingEndMark"> — </span>Clinical trials have found modest reductions in social anxiety disorder (SAD) symptoms with <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> or <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> monotherapy however, augmentation with these drugs has not been tested.</p><p>Other medication have yielded mixed or negative results in clinical trials or have not been sufficiently tested. Our choice of medication is based on clinical experience and patient preference.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Buspirone</strong> – A small uncontrolled trial found that 7 of 10 patients partially responsive to selective serotonin reuptake inhibitors (SSRIs) appeared to benefit from augmentation with <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">buspirone</a> [<a href="#rid37">37,39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gabapentin</strong><strong> </strong>– <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a> (an anticonvulsant) has demonstrated modest effectiveness (response rates &lt;45 percent) for SAD. In a randomized trial, 69 patients with SAD were assigned to treatment with either gabapentin (flexible dose between 900 and 3600 mg daily in three divided doses) or placebo for 14 weeks [<a href="#rid23">23</a>]. Patients receiving gabapentin experienced reduced SAD symptoms compared with patients receiving placebo. Adverse events were consistent with the known side effect profile of gabapentin (eg, dizziness, dry mouth, somnolence).</p><p></p><p class="bulletIndent1">Based upon case reports and human studies, the US Food and Drug Administration (FDA) issued a safety alert in 2019, warning that <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> may be associated with respiratory depression when administered to patients receiving central nervous system depressants or patients with underlying respiratory impairment [<a href="#rid40">40</a>]. In prescribing gabapentin to patients with these risk factors, we start the medication at a low dose (eg, 100 mg three times daily) and monitor for symptoms of respiratory depression while increasing slowly over several weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregabalin</strong><strong> </strong>– <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">Pregabalin</a>, a compound related to <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, has demonstrated modest effectiveness (response rates &lt;45 percent) in the treatment of generalized SAD [<a href="#rid25">25,26</a>]. Side effects include sedation and dizziness. Tolerance, withdrawal, and dependence are possible, but pregabalin is generally better tolerated than benzodiazepines. Doses of pregabalin for SAD typically range from 150 to 600 mg per day.</p><p></p><p class="bulletIndent1">The FDA issued a safety alert, warning that gabapentinoids may be associated with respiratory depression [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mirtazapine</strong> – <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">Mirtazapine</a> has shown mixed results in patients with SAD. In a randomized trial of 66 women with SAD, mirtazapine (30 mg a day) was found to be efficacious for SAD compared with placebo [<a href="#rid41">41</a>]. In a more recent randomized controlled trial of 60 males and females with generalized SAD randomized to either 30 to 45 mg/day of the medication or placebo for 12 weeks, mirtazapine was no more effective than placebo (13 versus 13 percent response rate) [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta-blockers</strong> –<strong> </strong>Beta-blockers are not an effective treatment for generalized SAD [<a href="#rid43">43-45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tricyclic antidepressants</strong> – The TCAs have not been well studied in clinical trials of patients with SAD. A small open-label trial of <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">imipramine</a> suggested that it was not effective. It is possible that TCAs with more potent serotonergic reuptake blockade (eg, <a class="drug drug_general" data-topicid="9283" href="/z/d/drug information/9283.html" rel="external">clomipramine</a>) might be useful, but this is unknown.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second-generation antipsychotics </strong>– Very small randomized controlled trials of <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> and <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> suggested that these atypical (or “second-generation”) antipsychotics might be effective for SAD [<a href="#rid46">46,47</a>]. Further study is needed as well as consideration of metabolic side effects of these agents [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">Atomoxetine</a><strong> </strong>– In one small trial, atomoxetine was not shown to be effective for SAD [<a href="#rid49">49</a>]. Some evidence suggests that atomoxetine may be helpful in adults with comorbid ADHD and SAD [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ketamine</strong> – More work is needed to determine the efficacy and safety of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> infusions for SAD. In a small trial including 18 adults with SAD, a single dose of intravenous ketamine (0.5 mg/kg over 40 minutes) was associated with a higher rate of treatment response (defined as &gt;35 percent reduction on the Liebowitz Social Anxiety Scale (LSAS) as compared with placebo in the first two weeks following infusion (33.3 versus 0 percent) [<a href="#rid51">51</a>]. The response rate to both treatments is low.</p><p></p><p class="headingAnchor" id="H2288380316"><span class="h1">MEDICATION RESISTANCE</span><span class="headingEndMark"> — </span>For patients who do not respond to any one or all of these medications, cognitive-behavioral therapy (CBT) remains an option, either as monotherapy or in conjunction with the medication providing some benefit. (See  <a class="medical medical_review" href="/z/d/html/14635.html" rel="external">"Social anxiety disorder in adults: Psychotherapy", section on 'Cognitive-behavioral therapy'</a>.)</p><p class="headingAnchor" id="H1299638998"><span class="h1">SOCIAL ANXIETY DISORDER, PERFORMANCE ONLY</span><span class="headingEndMark"> — </span>For most patients with social anxiety disorder (SAD), performance only, particularly those who will encounter performance symptoms on a recurring basis, we suggest first-line treatment with cognitive-behavioral therapy (CBT) for SAD.</p><p>For a patient requesting help with a single or rarely recurring performance (eg, giving the toast at a friend’s wedding), pharmacotherapy may be a suitable alternative. When medication is used, either a beta-adrenergic blocker or a benzodiazepine can be given 30 to 60 minutes before the performance. We avoid using benzodiazepines if the person is planning on drinking alcohol. Patients should try the medication in advance of a potentially precipitating event; a dose adjustment may be needed for effectiveness or side effects.</p><p>We would be more inclined to use a beta blocker in patients who have prominent awareness of physiological symptoms such as tachycardia or tremor.</p><p>Patients with public-speaking anxiety can benefit from exposure to practicing public speaking in classes or clubs such as Toastmasters, but generally only after the completion of a course of CBT. (See  <a class="medical medical_review" href="/z/d/html/14635.html" rel="external">"Social anxiety disorder in adults: Psychotherapy", section on 'Administration'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta adrenergic blockers</strong> – Several small trials found beta-blockers to reduce performance anxiety, although not in patients diagnosed with SAD [<a href="#rid43">43,52</a>]. Beta-blockers are nonetheless used at times for the management of performance anxiety. Clinical experience suggests that only half (or fewer) people find as-needed beta-blockers useful for performance anxiety.</p><p></p><p class="bulletIndent1">Our preference is to use <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> as it is lipophilic and crosses the blood brain barrier. When prescribing propranolol, we tell the patient to take 10 to 20 mg orally 30 to 60 minutes prior to the anxiety-inducing situation. We encourage the patient to try out the medication in advance of a potentially precipitating event to determine how well it is tolerated and to see if it is efficacious. If tolerated but not sufficiently effective, we suggest increasing the dose by 10 or 20 mg for the next time. Some patients may eventually require a dose of 60 mg. Contraindications to the prescription of beta-blockers include: a history of beta-blocker intolerance or allergy, diabetes, and certain cardiac conditions (eg, conduction problems). (See  <a class="medical medical_review" href="/z/d/html/967.html" rel="external">"Major side effects of beta blockers"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benzodiazepines</strong> – Benzodiazepines can also be used on an "as needed" basis to treat SAD, performance only [<a href="#rid53">53</a>]. We typically give doses of <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a> 0.25 to 1 mg or <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> 0.5 to 2 mg 30 to 60 minutes before the performance. Sedation can be a side effect of benzodiazepines, particularly at higher doses. For this reason, the patient should be encouraged to try out the medication in advance of a potentially precipitating event to determine how well it is tolerated and to see if it is efficacious.</p><p></p><p class="bulletIndent1">Tolerance and physical dependence are less of a concern with occasional use. However, the potential for misuse, highest in persons with a history of alcohol or other substance use limit their use in this context. Patients may have used alcohol in the past to cope with similar situations and should be explicitly cautioned not to mix alcohol with benzodiazepines. The efficacy and side effects of benzodiazepines are reviewed above. (See <a class="local">'No substance use disorder'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cannabinoids</strong> – As the evidence in support of cannabinoids in the treatment of SAD in adults is sparse, we do not recommend the use of cannabinoids in the treatment of SAD. </p><p></p><p class="bulletIndent1">In a small study, 24 subjects with a diagnosis of SAD but without prior treatment were randomly assigned to receive, 600 mg cannabidiol (n = 12) or placebo (n = 12) prior to a public speaking task. Treatment with cannabidiol resulted in reduced anxiety, cognitive impairment, and discomfort during their speech performance as compared with those receiving placebo [<a href="#rid54">54</a>]. However, in another trial, treatment with cannabidiol did not enhance the effects of exposure therapy in subjects with SAD and panic disorder with agoraphobia [<a href="#rid55">55</a>].</p><p></p><p class="headingAnchor" id="H3473001932"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113096.html" rel="external">"Society guideline links: Anxiety and anxiety disorders in adults"</a>.)</p><p class="headingAnchor" id="H2691862838"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Social anxiety disorder (SAD) </strong>– SAD is a disorder manifested by extreme fear of situations that involve possible scrutiny by others leading to embarrassment or humiliation. The individual either avoids such situations or endures them with intense anxiety. SAD may be generalized or limited to performance situations only. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selecting treatment</strong> – Psychotherapy and medication are each effective for this disorder. Studies do not suggest greater effect of one treatment over the other or combined treatment over either alone. Our choice is based on informed patient preference and/or availability. (See <a class="local">'Selection of treatment modality'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preference for psychotherapy </strong>– For patients who prefer psychotherapy, we suggest treatment with individual or group CBT, customized for SAD, rather than other psychotherapies (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Patients who prefer psychotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preference for medication</strong> – For patients who prefer medication, we suggest treatment with a serotonin reuptake inhibitor (selective serotonin reuptake inhibitor [SSRI] or serotonin-norepinephrine reuptake inhibitor [SNRI]) rather than other medications (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Selecting a medication'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inadequate response </strong>– For patients with partial or no response to initial management we reassess for the presence of undiagnosed comorbid disorder. After addressing this, if symptoms persist our preference is as follows (see <a class="local">'Initial adjustments'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Response to CBT</strong> – For inadequate response to CBT, we assess for remaining cognitive errors or avoidance strategies and address this with additional CBT. (See <a class="local">'Patients who prefer psychotherapy'</a> above.)</p><p></p><p class="bulletIndent2">If this is unsuccessful, we treat with a combination of CBT and an SSRI/SNRI.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Response to medication</strong> – For inadequate response to initial pharmacological management (with or without combined psychotherapy), we assess for and address adherence to medication and treatment limiting side effects. (See <a class="local">'Initial adjustments'</a> above.)</p><p></p><p class="bulletIndent2">For individuals with no response to initial SSRI/SNRI agent, we suggest a trial of a second SSRI/SNRI rather than augmentation methods (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2">For partial response to SSRI/SNRI we prefer augmentation methods. Our choice depends on whether there is a substance use disorder. (See <a class="local">'Subsequent pharmacologic management'</a> above.)</p><p></p><p class="bulletIndent2">For no response to two SSRI/SNRI agents we switch agents. Our next choice depends on whether there is a substance use disorder. (See <a class="local">'Subsequent pharmacologic management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>No substance use disorder</strong> – For individuals without a substance use disorder, we suggest a trial of benzodiazepine rather than other medications (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We add the benzodiazepine to the SSRI for those with a partial response; we switch to a benzodiazepine for no response. (See <a class="local">'No substance use disorder'</a> above.)</p><p></p><p class="bulletIndent2">If symptoms persist our next choice of agent depends on the level of response to the treatment with the benzodiazepine.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For no response, we switch to a monoamine oxidase inhibitor (MAOI) as monotherapy. If MAOI is ineffective we treat with sequential trials of <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">buspirone</a>, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For partial response, our preference is augmentation methods. Our preference is sequential trials of <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">buspirone</a>, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>. We do not combine SSRI/SNRI with MAOIs.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Substance use disorder</strong> – For individuals with a substance use disorder, we typically avoid benzodiazepines. (See <a class="local">'Substance use disorder'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For no response to SSRI/SNRI, we switch to MAOI monotherapy. If this is ineffective, we prefer sequential trials of <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">buspirone</a>, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For partial response to SSRI/SNRI treatment, minimal data guides our treatment. We prefer subsequent augmentation trials of <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">buspirone</a>, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>. We do not combine MAOI with SSRI/SNRI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SAD, performance only</strong> – For patients with SAD, performance only, who will encounter performance situations on a reoccurring basis, we suggest first-line treatment with CBT tailored for SAD (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Social anxiety disorder, performance only'</a> above.)</p><p></p><p class="bulletIndent1">For a patient needing help with a single or rarely reoccurring performance, pharmacotherapy may be preferred. (See <a class="local">'Social anxiety disorder, performance only'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ruscio AM, Brown TA, Chiu WT, et al. Social fears and social phobia in the USA: results from the National Comorbidity Survey Replication. Psychol Med 2008; 38:15.</a></li><li><a class="nounderline abstract_t">Blanco C, Heimberg RG, Schneier FR, et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry 2010; 67:286.</a></li><li><a class="nounderline abstract_t">Davidson JR, Foa EB, Huppert JD, et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 2004; 61:1005.</a></li><li><a class="nounderline abstract_t">Blomhoff S, Haug TT, Hellström K, et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 2001; 179:23.</a></li><li><a class="nounderline abstract_t">Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 1998; 55:1133.</a></li><li><a class="nounderline abstract_t">Stein MB, Stein DJ. Social anxiety disorder. Lancet 2008; 371:1115.</a></li><li><a class="nounderline abstract_t">Clark DM, Ehlers A, McManus F, et al. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol 2003; 71:1058.</a></li><li class="breakAll">Hofmann, SG, Otto, MW. Cognitive-behavior therapy of social phobia: Evidence-based and disorder specific treatment techniques, Routledge, New York 2008.</li><li><a class="nounderline abstract_t">Amir N, Beard C, Taylor CT, et al. Attention training in individuals with generalized social phobia: A randomized controlled trial. J Consult Clin Psychol 2009; 77:961.</a></li><li><a class="nounderline abstract_t">Schmidt NB, Richey JA, Buckner JD, Timpano KR. Attention training for generalized social anxiety disorder. J Abnorm Psychol 2009; 118:5.</a></li><li><a class="nounderline abstract_t">Beard C, Sawyer AT, Hofmann SG. Efficacy of attention bias modification using threat and appetitive stimuli: a meta-analytic review. Behav Ther 2012; 43:724.</a></li><li><a class="nounderline abstract_t">Lipsitz JD, Gur M, Vermes D, et al. A randomized trial of interpersonal therapy versus supportive therapy for social anxiety disorder. Depress Anxiety 2008; 25:542.</a></li><li><a class="nounderline abstract_t">Hofmann SG, Smits JA. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry 2008; 69:621.</a></li><li><a class="nounderline abstract_t">Barkowski S, Schwartze D, Strauss B, et al. Efficacy of group psychotherapy for social anxiety disorder: A meta-analysis of randomized-controlled trials. J Anxiety Disord 2016; 39:44.</a></li><li><a class="nounderline abstract_t">Mayo-Wilson E, Dias S, Mavranezouli I, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry 2014; 1:368.</a></li><li><a class="nounderline abstract_t">Stangier U, Schramm E, Heidenreich T, et al. Cognitive therapy vs interpersonal psychotherapy in social anxiety disorder: a randomized controlled trial. Arch Gen Psychiatry 2011; 68:692.</a></li><li><a class="nounderline abstract_t">Leichsenring F, Salzer S, Beutel ME, et al. Long-term outcome of psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder. Am J Psychiatry 2014; 171:1074.</a></li><li><a class="nounderline abstract_t">Leichsenring F, Salzer S, Beutel ME, et al. Psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder: a multicenter randomized controlled trial. Am J Psychiatry 2013; 170:759.</a></li><li><a class="nounderline abstract_t">Bögels SM, Wijts P, Oort FJ, Sallaerts SJ. Psychodynamic psychotherapy versus cognitive behavior therapy for social anxiety disorder: an efficacy and partial effectiveness trial. Depress Anxiety 2014; 31:363.</a></li><li><a class="nounderline abstract_t">Stein DJ, Ipser JC, Balkom AJ. Pharmacotherapy for social phobia. Cochrane Database Syst Rev 2004; :CD001206.</a></li><li><a class="nounderline abstract_t">Gelernter CS, Uhde TW, Cimbolic P, et al. Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry 1991; 48:938.</a></li><li><a class="nounderline abstract_t">Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993; 13:423.</a></li><li><a class="nounderline abstract_t">Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999; 19:341.</a></li><li><a class="nounderline abstract_t">Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004; 24:141.</a></li><li><a class="nounderline abstract_t">Lydiard RB, Rickels K, Herman B, Feltner DE. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol 2010; 13:229.</a></li><li><a class="nounderline abstract_t">Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 2007; 27:263.</a></li><li><a class="nounderline abstract_t">Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005; 62:190.</a></li><li><a class="nounderline abstract_t">Liebowitz MR, Mangano RM, Bradwejn J, et al. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 2005; 66:238.</a></li><li><a class="nounderline abstract_t">Stein MB, Pollack MH, Bystritsky A, et al. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl) 2005; 177:280.</a></li><li><a class="nounderline abstract_t">Williams T, Hattingh CJ, Kariuki CM, et al. Pharmacotherapy for social anxiety disorder (SAnD). Cochrane Database Syst Rev 2017; 10:CD001206.</a></li><li><a class="nounderline abstract_t">Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry 2010; 71:839.</a></li><li><a class="nounderline abstract_t">Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998; 59:502.</a></li><li><a class="nounderline abstract_t">Mennin DS, Fresco DM, Heimberg RG, et al. Screening for social anxiety disorder in the clinical setting: using the Liebowitz Social Anxiety Scale. J Anxiety Disord 2002; 16:661.</a></li><li><a class="nounderline abstract_t">Heimberg RG, Horner KJ, Juster HR, et al. Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol Med 1999; 29:199.</a></li><li><a class="nounderline abstract_t">Pollack MH, Van Ameringen M, Simon NM, et al. A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry 2014; 171:44.</a></li><li><a class="nounderline abstract_t">Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998; 280:708.</a></li><li><a class="nounderline abstract_t">Van Ameringen M, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord 1996; 39:115.</a></li><li><a class="nounderline abstract_t">Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry 2004; 65:244.</a></li><li><a class="nounderline abstract_t">van Vliet IM, den Boer JA, Westenberg HG, Pian KL. Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry 1997; 58:164.</a></li><li class="breakAll">United States Food and Drug Administration. FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR): When used with CNS depressants or in patients with lung problems. December 19, 2019. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin (Accessed on April 11, 2020).</li><li><a class="nounderline abstract_t">Muehlbacher M, Nickel MK, Nickel C, et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2005; 25:580.</a></li><li><a class="nounderline abstract_t">Schutters SI, Van Megen HJ, Van Veen JF, et al. Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol 2010; 25:302.</a></li><li><a class="nounderline abstract_t">Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 1992; 49:290.</a></li><li><a class="nounderline abstract_t">Turner SM, Beidel DC, Jacob RG. Social phobia: a comparison of behavior therapy and atenolol. J Consult Clin Psychol 1994; 62:350.</a></li><li><a class="nounderline abstract_t">Stein MB, Sareen J, Hami S, Chao J. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001; 158:1725.</a></li><li><a class="nounderline abstract_t">Vaishnavi S, Alamy S, Zhang W, et al. Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1464.</a></li><li><a class="nounderline abstract_t">Barnett SD, Kramer ML, Casat CD, et al. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 2002; 16:365.</a></li><li><a class="nounderline abstract_t">Depping AM, Komossa K, Kissling W, Leucht S. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev 2010; :CD008120.</a></li><li><a class="nounderline abstract_t">Ravindran LN, Kim DS, Letamendi AM, Stein MB. A randomized controlled trial of atomoxetine in generalized social anxiety disorder. J Clin Psychopharmacol 2009; 29:561.</a></li><li><a class="nounderline abstract_t">Adler LA, Liebowitz M, Kronenberger W, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety 2009; 26:212.</a></li><li><a class="nounderline abstract_t">Taylor JH, Landeros-Weisenberger A, Coughlin C, et al. Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial. Neuropsychopharmacology 2018; 43:325.</a></li><li><a class="nounderline abstract_t">Steenen SA, van Wijk AJ, van der Heijden GJ, et al. Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis. J Psychopharmacol 2016; 30:128.</a></li><li class="breakAll">Ravindran LN, Stein MB. Anxiety Disorders: Somatic Treatment. In: Kaplan and Sadock Comprehensive Textbook of Psychiatry, 9th ed, Sadock BJ, Sadock VA, Ruiz P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, PA 2009. p.1906.</li><li><a class="nounderline abstract_t">Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 2011; 36:1219.</a></li><li><a class="nounderline abstract_t">Kwee CM, Baas JM, van der Flier FE, et al. Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: A randomised controlled trial. Eur Neuropsychopharmacol 2022; 59:58.</a></li></ol></div><div id="topicVersionRevision">Topic 108042 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17976249" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Social fears and social phobia in the USA: results from the National Comorbidity Survey Replication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20194829" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15466674" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11435264" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9862558" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18374843" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Social anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14622081" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14622081" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19803575" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Attention training in individuals with generalized social phobia: A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19222309" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Attention training for generalized social anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23046776" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Efficacy of attention bias modification using threat and appetitive stimuli: a meta-analytic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17941096" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A randomized trial of interpersonal therapy versus supportive therapy for social anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18363421" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26953823" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Efficacy of group psychotherapy for social anxiety disorder: A meta-analysis of randomized-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26361000" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21727253" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cognitive therapy vs interpersonal psychotherapy in social anxiety disorder: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25016974" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Long-term outcome of psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23680854" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder: a multicenter randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24577880" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Psychodynamic psychotherapy versus cognitive behavior therapy for social anxiety disorder: an efficacy and partial effectiveness trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15495010" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pharmacotherapy for social phobia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1929764" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8120156" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Treatment of social phobia with clonazepam and placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10440462" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Treatment of social phobia with gabapentin: a placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15206660" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19737439" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17502773" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699296" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15705011" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15258718" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29048739" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pharmacotherapy for social anxiety disorder (SAnD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20667290" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The pharmacologic treatment of anxiety disorders: a review of progress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9818630" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12405524" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Screening for social anxiety disorder in the clinical setting: using the Liebowitz Social Anxiety Scale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10077308" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Psychometric properties of the Liebowitz Social Anxiety Scale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24399428" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9728642" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8827420" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15003080" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9164427" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9164427" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16282842" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20715300" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1558463" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Phenelzine vs atenolol in social phobia. A placebo-controlled comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8201073" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Social phobia: a comparison of behavior therapy and atenolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11579011" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17698275" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12503837" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Efficacy of olanzapine in social anxiety disorder: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21154392" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Second-generation antipsychotics for anxiety disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19910721" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A randomized controlled trial of atomoxetine in generalized social anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19194995" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28849779" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26487439" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26487439" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21307846" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35561538" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: A randomised controlled trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
